NBIX Quote, Financials, Valuation and Earnings

AptarGroup has a net margin of 20.87% compared to Neurocrine Biosciences's net margin of 11%. Neurocrine Biosciences's return on equity of 16.29% beat AptarGroup's return on equity of 14.16%.

Neurocrine Biosciences has a consensus price target of $165.72, signalling upside risk potential of 19.2%. On the other hand AptarGroup has an analysts' consensus of $148.43 which suggests that it could grow by 18.35%. Given that Neurocrine Biosciences has higher upside potential than AptarGroup, analysts believe Neurocrine Biosciences is more attractive than AptarGroup.

Neurocrine Biosciences has a beta of 0.340, which suggesting that the stock is 65.953% less volatile than S&P 500. In comparison AptarGroup has a beta of 0.577, suggesting its less volatile than the S&P 500 by 42.257%.

Neurocrine Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AptarGroup offers a yield of 1.08% to investors and pays a quarterly dividend of $0.45 per share. Neurocrine Biosciences pays -- of its earnings as a dividend. AptarGroup pays out 36.45% of its earnings as a dividend. AptarGroup's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Neurocrine Biosciences quarterly revenues are $622.1M, which are smaller than AptarGroup quarterly revenues of $909.3M. Neurocrine Biosciences's net income of $129.8M is higher than AptarGroup's net income of $100M. Notably, Neurocrine Biosciences's price-to-earnings ratio is 37.27x while AptarGroup's PE ratio is 31.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neurocrine Biosciences is 6.42x versus 3.00x for AptarGroup. Usually stocks with elevated PS ratios are considered overvalued.

The Cooper Companies has a net margin of 20.87% compared to Neurocrine Biosciences's net margin of 11.54%. Neurocrine Biosciences's return on equity of 16.29% beat The Cooper Companies's return on equity of 5.02%.

Neurocrine Biosciences has a consensus price target of $165.72, signalling upside risk potential of 19.2%. On the other hand The Cooper Companies has an analysts' consensus of $112.01 which suggests that it could grow by 20.95%. Given that The Cooper Companies has higher upside potential than Neurocrine Biosciences, analysts believe The Cooper Companies is more attractive than Neurocrine Biosciences.

Neurocrine Biosciences has a beta of 0.340, which suggesting that the stock is 65.953% less volatile than S&P 500. In comparison The Cooper Companies has a beta of 0.968, suggesting its less volatile than the S&P 500 by 3.236%.

Neurocrine Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. The Cooper Companies offers a yield of 0% to investors and pays a quarterly dividend of $0.01 per share. Neurocrine Biosciences pays -- of its earnings as a dividend. The Cooper Companies pays out -- of its earnings as a dividend.

Neurocrine Biosciences quarterly revenues are $622.1M, which are smaller than The Cooper Companies quarterly revenues of $1B. Neurocrine Biosciences's net income of $129.8M is higher than The Cooper Companies's net income of $117.5M. Notably, Neurocrine Biosciences's price-to-earnings ratio is 37.27x while The Cooper Companies's PE ratio is 47.49x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neurocrine Biosciences is 6.42x versus 4.76x for The Cooper Companies. Usually stocks with elevated PS ratios are considered overvalued.

Repligen has a net margin of 20.87% compared to Neurocrine Biosciences's net margin of -0.42%. Neurocrine Biosciences's return on equity of 16.29% beat Repligen's return on equity of -0.41%.

Neurocrine Biosciences has a consensus price target of $165.72, signalling upside risk potential of 19.2%. On the other hand Repligen has an analysts' consensus of $191.46 which suggests that it could grow by 31.34%. Given that Repligen has higher upside potential than Neurocrine Biosciences, analysts believe Repligen is more attractive than Neurocrine Biosciences.

Neurocrine Biosciences has a beta of 0.340, which suggesting that the stock is 65.953% less volatile than S&P 500. In comparison Repligen has a beta of 0.965, suggesting its less volatile than the S&P 500 by 3.502%.

Neurocrine Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Repligen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neurocrine Biosciences pays -- of its earnings as a dividend. Repligen pays out -- of its earnings as a dividend.

Neurocrine Biosciences quarterly revenues are $622.1M, which are larger than Repligen quarterly revenues of $154.9M. Neurocrine Biosciences's net income of $129.8M is higher than Repligen's net income of -$654K. Notably, Neurocrine Biosciences's price-to-earnings ratio is 37.27x while Repligen's PE ratio is 628.56x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neurocrine Biosciences is 6.42x versus 12.93x for Repligen. Usually stocks with elevated PS ratios are considered overvalued.

West Pharmaceutical Services has a net margin of 20.87% compared to Neurocrine Biosciences's net margin of 18.21%. Neurocrine Biosciences's return on equity of 16.29% beat West Pharmaceutical Services's return on equity of 18.16%.

Neurocrine Biosciences has a consensus price target of $165.72, signalling upside risk potential of 19.2%. On the other hand West Pharmaceutical Services has an analysts' consensus of $378.17 which suggests that it could grow by 13.42%. Given that Neurocrine Biosciences has higher upside potential than West Pharmaceutical Services, analysts believe Neurocrine Biosciences is more attractive than West Pharmaceutical Services.

Neurocrine Biosciences has a beta of 0.340, which suggesting that the stock is 65.953% less volatile than S&P 500. In comparison West Pharmaceutical Services has a beta of 1.007, suggesting its more volatile than the S&P 500 by 0.671%.

Neurocrine Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. West Pharmaceutical Services offers a yield of 0.24% to investors and pays a quarterly dividend of $0.21 per share. Neurocrine Biosciences pays -- of its earnings as a dividend. West Pharmaceutical Services pays out 9.61% of its earnings as a dividend. West Pharmaceutical Services's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Neurocrine Biosciences quarterly revenues are $622.1M, which are smaller than West Pharmaceutical Services quarterly revenues of $746.9M. Neurocrine Biosciences's net income of $129.8M is lower than West Pharmaceutical Services's net income of $136M. Notably, Neurocrine Biosciences's price-to-earnings ratio is 37.27x while West Pharmaceutical Services's PE ratio is 49.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neurocrine Biosciences is 6.42x versus 8.58x for West Pharmaceutical Services. Usually stocks with elevated PS ratios are considered overvalued.